COMP <GO>
KRYS vs LLY // 10Y YIELD & FRED MACRO BETA
Krystal Biotech Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: KRYS 5
— LLY 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: KRYS
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
macro-sensitivity
0.91
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 32.36% | -15.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | 36.4x | +16.98 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 2.30% | -0.33 | LLY | /fcf-yield <GO> |
| Operating Margin | 41.50% | 40.21% | +1.29 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 31.90% | +20.70 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | 45.51% | -11.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | KRYS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 77.9 | -24.10 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.91 | 0.51 | +0.40 | KRYS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 26.3x | +13.15 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | LLY REV | KRYS GROSS % | LLY GROSS % | KRYS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $65.18B | 44.0% | 83.0% | $188.9M | $16.81B |
| FY 2024 | $290.5M | $45.04B | 44.0% | 81.3% | $119.2M | $8.82B |
| FY 2023 | $50.7M | $34.12B | 44.0% | 79.3% | -$91.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
LLY // BETA 0.51